Cours suspendu

Communiqués eFFECTOR Therapeutics, Inc. Deutsche Boerse AG

Actions

LWK1

US28202V1089

Recherche biotechnologique et médicale

Temps Différé Deutsche Boerse AG Autres places de cotation 09:59:01 24/06/2024			Varia. 5j.	Varia. 1 janv.
1,075 ^EUR	+0,47%		-8,12%	-88,97%

10/09/24	Tyra Biosciences nomme Doug Warner directeur médical	MT
24/06/24	Mise à jour sectorielle : Les actions du secteur de la santé augmentent en fin d'après-midi	MT

Communiqués

13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
05/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ
25/01/24	EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	AQ
09/01/24	EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	GL
09/01/24	EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	AQ
09/01/24	EFFECTOR Therapeutics Announces Reverse Stock Split	AQ
09/01/24	EFFECTOR Therapeutics Announces Reverse Stock Split	GL
11/12/23	EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS	AQ
08/12/23	EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	GL
08/12/23	EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	AQ
28/11/23	EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer	GL
27/11/23	The role of STRIs in cancer	AQ
15/11/23	EFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting	GL
13/11/23	EFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	GL
06/11/23	EFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference	AQ
06/11/23	EFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference	GL
25/10/23	EFFECTOR THERAPEUTICS TO COLLABORATE WITH THE NORTHWESTERN UNIVERSITY DIVISION OF HEMATOLOGY AND ONCOLOGY ON AN INVESTIGATOR-INITIATED PHASE 1 DOSE ESCALATION TRIAL	AQ
24/10/23	EFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia	AQ
24/10/23	EFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia	GL
11/09/23	EFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors	GL
30/08/23	EFFECTOR Therapeutics to Participate in Upcoming Investor Conferences	GL
09/08/23	EFFECTOR THERAPEUTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	AQ